AstraZeneca aims to nearly double revenues to $80bn by 2030

UK’s biggest drugmaker says it plans to launch 20 major new medicines before the end of the decade

Britain’s biggest drugmaker, AstraZeneca, has set out a bold ambition to reach $80bn (£63bn) in revenues by 2030 from treatments for cancer, rare diseases and other conditions, by launching 20 major new medicines before the end of the decade.

As the company prepared to present its growth plans to shareholders at its labs and corporate headquarters in Cambridge, it said many of the 20 new drugs will have the potential to generate more than $5bn in annual revenues at their peak.